FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963334748> ?p ?o ?g. }

• W1963334748 endingPage "51" @default.
• W1963334748 startingPage "49" @default.
• W1963334748 abstract "Hematological OncologyVolume 34, Issue 1 p. 49-51 Letter to the Editor Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma Cinzia Pellegrini, Cinzia Pellegrini Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorRoberto Maglie, Roberto Maglie Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorLisa Argnani, Lisa Argnani Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorStefano Pileri, Stefano Pileri Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorPier Luigi Zinzani, Corresponding Author Pier Luigi Zinzani [email protected] Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this author Cinzia Pellegrini, Cinzia Pellegrini Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorRoberto Maglie, Roberto Maglie Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorLisa Argnani, Lisa Argnani Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorStefano Pileri, Stefano Pileri Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this authorPier Luigi Zinzani, Corresponding Author Pier Luigi Zinzani [email protected] Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, ItalySearch for more papers by this author First published: 22 September 2014 https://doi.org/10.1002/hon.2163Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Bartlett NL. Modern treatment of Hodgkin lymphoma. Curr Opin Hematol 2008; 15: 408–414. 2Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–2189. 3Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456–460. 4Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210–218. 5Josting A, Wolf J, Diehl V. Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000; 12: 403–411. 6Fermé C, Mounier N, Diviné M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475. 7Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404. 8Thomson KJ, Kayani I, Ardeshna K, et al. A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia 2013; 27: 1419–1422. 9Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424–436. 10Clozel T, Deau B, Benet C, et al. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation. Br J Haematol 2013; 162: 846–848. Citing Literature Volume34, Issue1March 2016Pages 49-51 ReferencesRelatedInformation" @default.
• W1963334748 created "2016-06-24" @default.
• W1963334748 creator A5037030903 @default.
• W1963334748 creator A5043985252 @default.
• W1963334748 creator A5044832096 @default.
• W1963334748 creator A5046793649 @default.
• W1963334748 creator A5058320427 @default.
• W1963334748 date "2014-09-22" @default.
• W1963334748 modified "2023-10-16" @default.
• W1963334748 title "Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma" @default.
• W1963334748 cites W1856398768 @default.
• W1963334748 cites W1860199933 @default.
• W1963334748 cites W2041032819 @default.
• W1963334748 cites W2069656830 @default.
• W1963334748 cites W2145010435 @default.
• W1963334748 cites W2153280042 @default.
• W1963334748 cites W2155256323 @default.
• W1963334748 cites W2157575968 @default.
• W1963334748 cites W2159905203 @default.
• W1963334748 cites W2317418958 @default.
• W1963334748 doi "https://doi.org/10.1002/hon.2163" @default.
• W1963334748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25243375" @default.
• W1963334748 hasPublicationYear "2014" @default.
• W1963334748 type Work @default.
• W1963334748 sameAs 1963334748 @default.
• W1963334748 citedByCount "1" @default.
• W1963334748 countsByYear W19633347482016 @default.
• W1963334748 crossrefType "journal-article" @default.
• W1963334748 hasAuthorship W1963334748A5037030903 @default.
• W1963334748 hasAuthorship W1963334748A5043985252 @default.
• W1963334748 hasAuthorship W1963334748A5044832096 @default.
• W1963334748 hasAuthorship W1963334748A5046793649 @default.
• W1963334748 hasAuthorship W1963334748A5058320427 @default.
• W1963334748 hasConcept C120912362 @default.
• W1963334748 hasConcept C126322002 @default.
• W1963334748 hasConcept C17744445 @default.
• W1963334748 hasConcept C194409129 @default.
• W1963334748 hasConcept C199539241 @default.
• W1963334748 hasConcept C2779910751 @default.
• W1963334748 hasConcept C2911091166 @default.
• W1963334748 hasConcept C71924100 @default.
• W1963334748 hasConceptScore W1963334748C120912362 @default.
• W1963334748 hasConceptScore W1963334748C126322002 @default.
• W1963334748 hasConceptScore W1963334748C17744445 @default.
• W1963334748 hasConceptScore W1963334748C194409129 @default.
• W1963334748 hasConceptScore W1963334748C199539241 @default.
• W1963334748 hasConceptScore W1963334748C2779910751 @default.
• W1963334748 hasConceptScore W1963334748C2911091166 @default.
• W1963334748 hasConceptScore W1963334748C71924100 @default.
• W1963334748 hasIssue "1" @default.
• W1963334748 hasLocation W19633347481 @default.
• W1963334748 hasLocation W19633347482 @default.
• W1963334748 hasOpenAccess W1963334748 @default.
• W1963334748 hasPrimaryLocation W19633347481 @default.
• W1963334748 hasRelatedWork W1985640974 @default.
• W1963334748 hasRelatedWork W2004368639 @default.
• W1963334748 hasRelatedWork W2030025176 @default.
• W1963334748 hasRelatedWork W2042024967 @default.
• W1963334748 hasRelatedWork W2079994738 @default.
• W1963334748 hasRelatedWork W2084505320 @default.
• W1963334748 hasRelatedWork W2115228891 @default.
• W1963334748 hasRelatedWork W2168137348 @default.
• W1963334748 hasRelatedWork W2319149848 @default.
• W1963334748 hasRelatedWork W2884151677 @default.
• W1963334748 hasVolume "34" @default.
• W1963334748 isParatext "false" @default.
• W1963334748 isRetracted "false" @default.
• W1963334748 magId "1963334748" @default.
• W1963334748 workType "article" @default.